Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: Back to the future?

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 547-555

  Ribeiro, J T ^a   Macedo, L T ^b   Curigliano, G ^c   Fumagalli, L ^c   Locatelli, M ^c   Dalton, M ^d   Quintela, A ^a   Carvalheira, J B C ^b   Manunta, S ^e   Mazzarella, L ^c   Brollo, J ^c   Goldhirsch, A ^c  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SASSARI   (Italy)

Author keywords

Cytotoxic drugs; Metastatic breast cancer; New drugs

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYTOTOXIC AGENT; DOCETAXEL; ENDOTAG 1; EPIRUBICIN; ERIBULIN; GEMCITABINE; IXABEPILONE; LAROTAXEL; PACLITAXEL; PACLITAXEL POLIGLUMEX; TAXANE DERIVATIVE; TRABECTEDIN; TRASTUZUMAB; UNCLASSIFIED DRUG; VINFLUNINE;

ALOPECIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONSTIPATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HAIR LOSS; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTATIC BREAST CANCER; MONOTHERAPY; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETINA MACULA CYSTOID EDEMA; REVIEW; SARCOMA; SENSORY NEUROPATHY; TOXIC HEPATITIS; TRIPLE NEGATIVE BREAST CANCER;

EID: 84857554191     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr382     Document Type: Review

References (60)

1. Altekruse SF, Kossary CL, Krapcho M et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/ 1975_2007/(10 March 2011) based on November 2009 SEER data submission, posted to the SEER web site, 2010.
2. Cardoso F, Di LA, Lohrisch C et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002; 13: 197-207.
3. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23(31): 7794-7803.
4. Gradishar WJ, Krasnojon D, Cheporov S. Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer. J Clin Oncol 2009; 27(22): 3611-3619.
5. Lin NU, Parker LM, Come SE et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007; 2(5): 369-375.
6. Awada A, Bondarenko IN, Tarasova O et al. Results of the first randomized phase II study of Cationic Liposomal Paclitaxel (EndoTAGTM-1) targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann Oncol 2010: 21(8s) viii5 (Abstr LBA12).
7. Dié ras V, Limentani S, Romieu G et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxanebased therapy. Ann Oncol 2008; 19(7): 1255-1260.
8. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25(23): 3399-3406.
9. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25(23): 3407-3414.
10. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25(33): 5210-5217.
11. Sparano JA, Vrdoljak E, Rixe O et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; 28(20): 3256-3263.
12. Campone M, Cortes-Funes H, Vorobiof D et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/ taxane-based chemotherapy. Br J Cancer 2006; 95(9): 1161-1166.
13. Yardley DA, McCleod M, Schreiber F et al. A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest 2010; 28(9): 925-931.
14. Cortes J, Vahdat L, Blum JL et al. Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. J Clin Oncol 2010; 28(25): 3922-3928.
15. Cortes J, O'Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 openlabel randomised study. Lancet 2011; 377(9769): 914-923.
16. Twelves C, Cortes J, Vahdat LT et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010; 10(2): 160-163.
17. Zelek L, Yovine A, Brain E et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 2006; 94(11): 1610-1614.
18. Ghersi D, Wilcken N, Simes J et al. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2005; 2: CD003366.
19. Clarke R, Leonessa F, Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005; 32 (6 Suppl 7): S9-15.
20. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8(5): 1038-1044.
21. O'Brien ME, Socinski MA, Popovich AY et al. Randomized phase III trial comparing singleagent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-nai{dotless}̈ve advanced non-small cell lung cancer. J Thorac Oncol 2008; 3(7): 728-734.
22. Sabbatini P, Sill MW, O'Malley D et al. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): A gynecologic oncology group study. Gynecol Oncol 2008; 111(3): 455-460.
23. Treat J, Damjanov N, Huang C et al. Liposomal-encapsulated chemotherapy: preliminary results of a Phase I study of a novel liposomal paclitaxel. Oncology (Huntingt.) 2001; 15: 44-48.
24. Thurston G, McLean JW, Rizen M et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Investig 1998; 101: 1401-1413.
25. Löhr M, Haas S, Bechstein W et al. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: A phase II trial. J Clin Oncol 2009; 27(15s): 208s (Abstr 4526).
26. Bissery MC, Vrignaud P, Combeau C et al. Preclinical evaluation of XRP9881A, a new taxoid. Proceedings of the American Association of Cancer Research, 27-31 March 2004, Orlando, FL. (Abstr 5430).
27. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des 2001; 7: 1251-1257.
28. Kurata T, Shimada Y, Tamura T et al. Phase I and pharmacokinetics study of the new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 2000; 18: 3164-3171.
29. Gelmon KA, Latreille J, Tolcher A et al. Phase I dose-finding study of a new taxane, RPR109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J Clin Oncol 2000; 18: 4098-4108.
30. Sessa C, Cuvier C, Caldiera S et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 2002; 13: 1140-1150.
31. Gerth K, Bedorf N, Höfle G et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49(6): 560-563.
32. Gerth K, Bedorf N, Höfle G et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49(6): 560-563.
33. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007; 12(3): 271-280.
34. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55(11): 2325-2333.
35. Nettles JH, Li H, Cornett B et al. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science 2004; 305(5685): 866-869.
36. Bode CJ, Gupta ML Jr. Reiff EA et al. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41(12): 3870-3874.
37. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS- 247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10(4): 1289-1298.
38. Smith JW, Vukelja SJ, Rabe AC et al. Final results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer. Breast Cancer Symposium 2010/General Poster Session: (Abstr 268).
39. Lee F, Camuso A, Castenada S et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 2006; 24(18S): 597s (Abstr 12017).
40. Bunnell C, Vahdat L, Schwartzberg L et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008; 8(3): 234-241.
41. Gianni L, Dalenk F, De Benedictis E et al. Clinical and Pharmacokinetic Study of Ixabepilone plus Epirubicin as therapy for women with advanced breast cancer. Cancer Res 2009: 69(24s): (Abstr 2097).
42. Rugo RS, Campone M, Amadori A et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab versus paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer: final results. J Clin Oncol 2009; 27(15s): 47s (Abstr 1029).
43. Tolaney SM, Najita J, Chen W et al. A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. Cancer Research 2009; 69: 5472 (Abstr 3137).
44. Moulder S, Li H, Wang M, Gradishar WJ et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 2010; 119(3): 663-671.
45. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24(10): 1633-1642.
46. Kruczynski A, Poli M, Dossi R et al. Antiangiogenic, vascular-disrupting and antimetastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer 2006; 42(16): 2821-2832.
47. Culine S, Theodore C, De Santis M et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94(10): 1394-1401.
48. Bennouna J, Fumoleau P, Armand JP et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 2003; 14(4): 630-637.
49. Paridaens R, Wildiers H, Dalenc F et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J Clin Oncol 2007; 25(18s): 46s (Abstr 1058).
50. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res 2001; 61(3): 1013-1021.
51. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 in supression of microtubule growth. Mol Cancer Ther 2005; 4(7): 1086-1095.
52. Desai KK, Goel S, Mita A et al. Dose escalation and pharmacokinetic study of E 7389, a microtubule-binding drug in patients with advanced solid tumors. J Clin Oncol 2005; 23(16s): 214s (Abstr 3090).
53. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009; 27(18): 2954-2961.
54. Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65(7): 2964-2971.
55. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin- 743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001; 19(5): 1256-65.
56. Van Oosterom A, Maki R, Taron M et al. Correlation between the pattern of DNA repair efficiency and the natural history of patients with advanced sarcoma treated with ET-743 (Yondelis). ESMO Congress 2004: iii197 (Abstr 7450).
57. Delaloge S, Tedesco KL, Blum J et al. Preliminary safety and activity results of trabectidin in a phase II trial dedicated to triple-negative, HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer patients. J Clin Oncol 2009; 27(15s): 43s (Abstr 1010).
58. Tedesco KL, Blum JL, Goncalves A et al. A phase II trial of trabectedin in patients with HER2- positive and BRCA1/2 germ-line-mutated metastic breast cancer. J Clin Oncol 2010; 28(15s): 123s (Abstr 1038).
59. Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albuminbound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract 2009; 15(2): 67-78.
60. Dranitsaris G, Coleman R, Gradishar W. nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial. Breast Cancer Res Treat 2010; 119(3): 717-724.